FDA Approves Remdesivir As Treatment For Patients With COVID-19 Who Require Hospitalization
- October 23, 2020
USA Today (10/22, Rice) reports that on Thursday, the FDA “approved the antiviral drug remdesivir as a treatment for patients with COVID-19 who require hospitalization.” While the treatment was “previously authorized by the FDA for emergency use to treat COVID-19,” it “is now the first and only approved COVID-19 treatment in the United States, Gilead said in a release.”
The AP (10/22, Marchione) reports that the treatment “cut the time to recovery by five days – from 15 days to 10 on average – in a large study.”
Reuters (10/22, Beasley) reports that “also on Thursday, the FDA issued a new emergency use authorization for remdesivir to treat hospitalized pediatric patients under age 12 who weigh enough to receive an intravenous drug.”
Among the news outlets also reporting the story are NBC News (10/22, Edwards), Bloomberg (10/22, Langreth), the New York Times (10/22, Levenson), the Wall Street Journal (10/22, Walker, Subscription Publication), The Hill (10/22, Weixel), Newsweek (10/22, Roos), Politico (10/22, Brennan), CIDRAP (10/22, Schnirring), and TIME (10/22, Park).